This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
| INTRODUC TI ON
Sepsis, a devastating and life-threatening clinical condition, is caused by the dysregulated host immune response to a microbial infection, which can rapidly progress to organ dysfunction and death. 1,2 It is estimated to affect more than 30 million people worldwide each year according to WHO report 2018, and the mortality rate is as high as 30% for sepsis patients. 3, 4 Considering the facet of rapid progression and high mortality rate of sepsis, early identification of disease severity becomes essential for the evaluation of clinical treatment and the management of sepsis. 5 Acute physiology and chronic health evaluation (APACHE) II score and sequential organ failure assessment (SOFA) score are widely used for assessing sepsis risk and predicting prognosis in sepsis patients. 6, 7 However, they lack adequate specificity and require multiple measurements, leading to misleading results and unnecessary administration of antibiotics under some circumstances, which contribute to prolonged hospitalization stay and antibiotic resistance. 6, 8 Therefore, it is of great need to explore novel sensitive biomarkers with the potential for assisting on disease management and improving prognosis in sepsis patients.
With the wide application of high-throughput analysis, non-coding RNA is increasingly recognized as a regulator in various signaling pathways of inflammatory process in sepsis. 9 As a class of non-coding RNA, microRNAs (miRNAs) are endogenous small non-coding RNA with approximately 19-23 nucleotides in length that are involved in post-transcriptional regulations of gene expressions via impacting both the stability and translation of mRNAs. 10 As for miRNA-125 (miR-125) family, it is composed of miR-125a and miR-125b. 11 Prior studies elucidate that miR-125a and miR-125b are involved in the regulation of inflammatory responses and organ injuries. [12] [13] [14] For instance, one study that discloses the elevated expression of miR-125a is responsible for the upregulation of cytokines and chemokines such as interleukin (IL)-β, IL-6 and tumor necrosis factor-α (TNF-α) in lupus nephritis patients. 12 Another study reports on miR-125a and miR-125b, as hypoxia-regulated miRNAs, is involved in several hypoxia-induced organ dysfunctions such as heart and lung injuries through generating reactive oxygen species, protease inhibition, enzyme oxidation, and lipid peroxidation. 14 Based on these aforementioned studies, we hypothesized that miR-125a and miR-125b might participate in the development and progression of sepsis as well. However, limited related studies have been reported yet. Therefore, this study aimed to explore the predictive value of miR-125a and miR-125b for sepsis risk and their correlations with disease severity, inflammation, and 28-day mortality risk in sepsis patients.
| MATERIAL S AND ME THODS

| Participants
Between January 2017 and May 2019, 150 sepsis patients admitted to our hospital were consecutively enrolled in this study. The This study was approved by the Ethics Committee of our hospital. All participants or their guardians provided written informed consents before enrollment.
| Clinical data collection
Clinical characteristics of sepsis patients were documented after enrollment, including age, gender, body mass index (BMI), smoke status, and chronic comorbidities (such as chronic obstructive pulmonary disease (COPD), cardiomyopathy, chronic kidney failure, and cirrhosis). The laboratory indexes measured immediately after admission, such as serum creatinine (Scr), albumin, white blood cell (WBC), and C-reactive protein (CRP), were also recorded. Besides, APACHE II score and SOFA score were documented as well, which were evaluated within 24 hours after admission and used to assess severity of sepsis and severity of organ dysfunction.
| Sample collection
Blood samples of all sepsis patients were collected within 24 hours after admission, and the blood samples of HCs were collected on the enrollment. All blood samples were centrifuged at 1600 g for 10 minutes at 4℃. Subsequently, the supernatants were separated into Eppendorf tubes and further centrifuged at 12 000 g for 10 minutes at 4°C. Finally, the plasma was obtained and stored at −80°C until determination.
| Inflammatory cytokines measurement
The levels of TNF-α, IL-6, IL-17, and IL-23 in plasma from AIS patients were measured using commercial human enzyme-linked immune sorbent assay (ELISA) Kits (Abcam) in accordance with the manufacturer's protocol.
| MiR-125a and miR-125b detection
For sepsis patients and HCs, the relative expressions of miR-125a and miR-125b in plasma were detected by real-time quantitative polymerase chain reaction (qPCR). Firstly, total RNA was extracted from plasma using PureZOL RNA isolation reagent (Bio-Rad). Then, cDNA was synthesized using RT-PCR Quick Master Mix (Toyobo). Subsequently, qPCR was performed using SYBR Green Realtime PCR Master Mix (Toyobo). MiR-125a and miR-125b relative expressions were calculated by 2 −ΔΔCt using U6 as internal reference. 16, 17 Primers applied were as follows: MiR-125a, forward: 5' ACACTCCAGCTGGGTCCCTGAGACCCTTTAAC 3', reverse: 5' TGTCGTGGAGTCGGCAATTC 3'; miR-125b, forward: 5' ACACTCCAGCTGGGTCCCTGAGACCCTAACTT 3', reverse: 5' TGT CGTGGAGTCGGCAATTC 3'; U6, forward: 5' CTCGCTTCGGCAG CACATATACTA 3', reverse: 5' ACGAATTTGCGTGTCATCCTTGC 3'.
| Treatment and follow-up
Standard treatments and resuscitation were administered to patients after the diagnosis was established, which were performed as recommended by the International Guidelines for Management of Sepsis and Septic Shock. 18 All patients were followed up for 28 days, and the patients who died during the follow-up were recorded for evaluation of 28-day mortality. And all patients were categorized into survivors and deaths according to the survival status during 28day follow-up. 
| Statistical analysis
| RE SULTS
| Clinical characteristics
No difference of mean age (P = .153), gender (P = .472), or mean BMI (P = .253) was observed between sepsis patients and HCs.
In detail, the mean age was 56.9 ± 10.3 years in sepsis patients Abbreviations: APACHE II score, acute pathologic and chronic health evaluation II score; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; HCs, healthy controls; IL, interleukin; IQR, interquartile range; Scr, serum creatinine; SD, standard deviation; SOFA score, sequential organ failure assessment score; TNFα, tumor necrosis factor-α; WBC, white blood cell.
| Predictive value of miR-125a and miR-125b for sepsis risk
from HCs ( Figure 1C ). These data suggested that miR-125a and miR-125b could predict sepsis risk, and the predictive value of miR-125b for sepsis risk was superior to that of miR-125a numerically.
| Correlation of miR-125a with miR-125b in sepsis patients
In sepsis patients, the miR-125a relative expression was positively correlated with miR-125b relative expression (P < .001, r = .509; Figure 2 ).
| Correlation of miR-125a and miR-125b with APACHE II and SOFA scores in sepsis patients
In sepsis patients, miR-125a relative expression was positively correlated with APACHE II score (P < .001, r = .287; Figure 3A ) and SOFA score (P = .010, r = .209; Figure 3B ). Meanwhile, miR-125b relative expression was positively associated with APACHE II score (P < .001, r = .351; Figure 3C ) and SOFA score (P < .001, r = .278; Figure 3D) in sepsis patients. These data implied that both miR-125a and miR-125b relative expressions were positively associated with disease severity in sepsis patients.
| Correlation of miR-125a and miR-125b with inflammatory indexes in sepsis patients
In sepsis patients, no correlation of miR-125a relative expression with CRP (P = .074, r = .147; Figure 4A ), TNF-α (P = .930, r = .007; Figure 4B ), IL-6 (P = .368, r = .074; Figure 4C ), IL-17 (P = .619, r = .041; Figure 4D ), or IL-23 (P = .535, r = .051; Figure 4E ) was observed, while miR-125b relative expression was positively correlated with CRP (P < .001, r = .414; Figure 4F ), TNF-α (P = .002, r = .253; Figure 4G ), IL-6 (P < .001, r = .291; Figure 4H ), IL-17 (P < .001, r = .305; Figure 4I ), and IL-23 (P = .004, r = .233; Figure 4J ) in sepsis patients. These data indicated that there was no association of miR-125a relative expression with inflammation in sepsis patients, while miR-125b relative expression was positively associated with inflammation. Figure 5B ).
| Predictive value of miR-125a and miR-125b for 28-day mortality risk in sepsis patients
Furthermore, ROC curve analysis showed that miR-125a could not predict 28-day mortality risk in sepsis patients (AUC: 0.588, 95% CI: 0.491-0.685; Figure 5C ), while miR-125b (AUC: 0.699, 95% CI: 0.739, 95% CI: 0.655-0.823) were valuable for predicting increased 28-day mortality risk in sepsis patients. By numerical comparison, the predictive value of miR-125b for 28-day mortality risk was similar to that of CRP, APACHE II, and SOFA score. These data suggested that miR-125a lacked a predictive value for 28-day mortality risk in sepsis patients, while miR-125b presented a potential value for predicting increased 28-day mortality risk.
| D ISCUSS I ON
In the present study, we have discovered that: (a) MiR-125a and miR-125b could predict sepsis risk, and miR-125b exhibited a better predictive value for sepsis risk compared with miR-125a numerically. exhibited a potential predictive value for 28-day mortality risk.
MiR-125a and miR-125b have been implied in regulating innate and adaptive immunity during the etiology of different inflammatory and autoimmune diseases. 5, 11 Regarding miR-125a, it is located on chromosome 19 in a cluster with miR-99B and miR-7E, which enhances alternative activation of macrophages to assist inflammation. 19, 20 As for miR-125b, it promotes macrophage-mediated inflammation and upregulates co-stimulatory factor expression via suppressing interferon regulatory factor 4. 21 Evidence exhibit that miR-125a and miR-125b participate in regulating inflammatory responses and organ injuries. 14, 22 For instance, one study reveals that miR-125a predicts active disease status and is correlated with inflammation in patients with Crohn's disease. 22 Another study illuminates that miR-125b mediates the hypoxia-induced pulmonary hypertension through regulating apoptosis of airway epithelial cells, resulting in lung injury. 14 It is reported that miR-125b expression is involved in the regulating inflammation in RA and acute exacerbations of COPD (AECOPD). 14, 23 For instance, one study illustrates that miR-125b expression is positively associated with TNF-α, IL-6, and IL-1β in RA patients. 23 Another study displays that miR-125b expression is correlated with TNF-α, IL-1β, IL-8, and leukotriene B4 in patients with AECOPD. 14 However, limited study reports the association of miR-125b expression with inflammation in sepsis patients. Our study reported that miR-125b expression was positively associated with disease severity (APACHE II score and SOFA score) and inflammation (CRP, TNF-α, IL-6, IL-17, and IL-23) in sepsis patients. These might be explained 13, 14 In the present, further analysis of the role of miR-125a and miR-125b in predicting prognosis in sepsis patients reported that we also exhibited that the predictive value of miR-125b for 28-day mortality risk was similar compared with CRP, APACHE II score, and SOFA score. CRP, APACHE II score, and SOFA score are commonly clinically applied biomarkers and scoring systems for predicting mortality in sepsis patients; however, they lack adequate sensitivity and specificity. 6, 7 The findings in our study implied that the miR-125b might assist on improving the sensitivity and specificity of CRP, APACHE II score, and SOFA score for predicting prognosis in sepsis patients.
There were some limitations in our study: (a) The sample size of enrolled sepsis patients was relatively small, which might influence the statistic power, (b) Only 28-day mortality was evaluated, thus, the long-term effect of miR-125a and miR-125b on prognosis should be studied further, (c) The detailed mechanism of miR-125a and miR-125b in regulating the development and progression of sepsis were not investigated, thus, further experiments in exploring the detailed mechanism of miR-125a and miR-125b in sepsis should be carried out, and (d) Sepsis patients who died within 24 hours after admission were excluded, which might cause selection bias and limit the generalizability of findings.
In conclusion, miR-125a and miR-125b both predict increased sepsis risk, while only miR-125b correlates with elevated inflammation, disease severity, and 28-day mortality risk in sepsis patients.
These findings might offer some clues for sepsis risk identification, disease management, and prognosis prediction in sepsis patients in clinical practice.
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